Spots Global Cancer Trial Database for mucosal melanoma
Every month we try and update this database with for mucosal melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | NCT05549297 | Advanced Melano... | Tebentafusp Tebentafusp wit... Investigators C... | 18 Years - | Immunocore Ltd | |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | NCT00110019 | Mucosal Melanom... Recurrent Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M... | Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Placebo Sorafenib Tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | NCT02535078 | Malignant Melan... | Tebentafusp (IM... durvalumab tremelimumab | 18 Years - | Immunocore Ltd | |
| Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists | NCT02126579 | Melanoma Metastatic Mela... Mucosal Melanom... | Peptide Vaccine... PolyICLC Resiquimod IFA | 18 Years - | University of Virginia | |
| Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | NCT01961115 | Mucosal Melanom... Recurrent Melan... Recurrent Uveal... Stage IIIA Skin... Stage IIIA Uvea... Stage IIIB Skin... Stage IIIB Uvea... Stage IIIC Skin... Stage IIIC Uvea... Stage IV Skin M... Stage IV Uveal ... | Epacadostat MELITAC 12.1 Pe... | 18 Years - | Fred Hutchinson Cancer Center | |
| Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma | NCT03033576 | Clinical Stage ... Clinical Stage ... Melanoma of Unk... Mucosal Melanom... Unresectable Cu... Unresectable Me... | Ipilimumab Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | NCT04551352 | Cutaneous Melan... Uveal Melanoma Mucosal Melanom... | RO7293583 Tocilizumab Obinutuzumab Adalimumab | 18 Years - | Hoffmann-La Roche | |
| Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | NCT02858869 | Metastatic Mali... Metastatic Mela... Mucosal Melanom... Ocular Melanoma Stage IV Non-Sm... Stage IV Skin M... Melanoma of Unk... | Pembrolizumab Stereotactic Ra... | 18 Years - | Emory University | |
| Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib | NCT03235245 | Unresectable St... Stage IV Melano... | Nivolumab + Ipi... Encorafenib + B... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | NCT06319196 | Cutaneous Melan... Melanoma Stage ... Mucosal Melanom... | Opdualag Nivolumab | 18 Years - | University Health Network, Toronto | |
| A Study to Assess YH003 in Combination With Pebolizumab and Albumin Paclitaxel Injection in Subjects With Unresectable/Metastatic Mucosal Melanoma | NCT05420324 | Mucosal Melanom... | YH003 Pembrolizumab albumin paclita... | 18 Years - | Eucure (Beijing) Biopharma Co., Ltd | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV | NCT01166126 | Mucosal Melanom... Recurrent Melan... Stage IV Melano... | temsirolimus selumetinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured | NCT00798629 | Melanoma (Skin) | Autologous dend... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma | NCT05545969 | Mucosal Melanom... | Pembrolizumab Lenvatinib | 18 Years - 100 Years | Melanoma Institute Australia | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | NCT02158520 | Metastatic Mela... Mucosal Melanom... Stage IV Cutane... Stage IV Uveal ... Unresectable Me... | Bevacizumab Ipilimumab Laboratory Biom... Nab-paclitaxel Pharmacological... | 18 Years - | Academic and Community Cancer Research United | |
| Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study | NCT04462965 | Mucosal Melanom... | Toripalimab Temozolomide | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM | NCT05009446 | Mucosal Melanom... Sinonasal Melan... | endoscopic surg... intensity-modul... Chemotherapy dr... | 18 Years - | Eye & ENT Hospital of Fudan University | |
| Atypical MOLes and Melanoma Early Detection Study (MoleMed) | NCT04353050 | Melanoma Melanoma (Skin) Moles Nevus Nevus, Blue Nevus, Pigmente... Nevus, Spitz Nevi, Spindle C... Nevi, Dysplasti... Dysplastic Nevu... Mucosal Melanom... Mucosal Melanos... | Non-invasive ad... | 18 Years - | Russian Academy of Medical Sciences | |
| Neoadjuvant and Adjuvant Checkpoint Blockade | NCT02519322 | Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma | NCT01864538 | Metastatic Mela... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | NCT00110019 | Mucosal Melanom... Recurrent Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M... | Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Placebo Sorafenib Tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | NCT02978443 | Acral Lentigino... Mucosal Melanom... | Nivolumab Ipilimumab | 18 Years - | Georgetown University | |
| Apatinib Plus SHR1210 in Advanced Mucosal Melanoma | NCT03986515 | Mucosal Melanom... Advanced Cancer Apatinib SHR-1210 | apatinib plus S... | 18 Years - 75 Years | Henan Cancer Hospital | |
| Neoadjuvant and Adjuvant Checkpoint Blockade | NCT02519322 | Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma | NCT01864538 | Metastatic Mela... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. | NCT03602547 | Mucosal Melanom... | CM082 plus JS00... | 18 Years - 75 Years | AnewPharma | |
| Dinaciclib in Treating Patients With Stage IV Melanoma | NCT00937937 | Acral Lentigino... Cutaneous Nodul... Lentigo Maligna... Low-CSD Melanom... Mucosal Melanom... Recurrent Melan... Stage IV Cutane... | Dinaciclib | 18 Years - | National Cancer Institute (NCI) | |
| Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery | NCT00700882 | Melanoma (Skin) | dasatinib | 18 Years - | Eastern Cooperative Oncology Group | |
| Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | NCT05482074 | Recurrent Metas... Cutaneous Melan... Mucosal Melanom... Uveal Melanoma | Olaparib | 18 Years - | Dana-Farber Cancer Institute | |
| Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured | NCT00798629 | Melanoma (Skin) | Autologous dend... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma | NCT04472806 | Mucosal Melanom... | Toripalimab chemotherapy in... | 18 Years - 75 Years | Fudan University | |
| A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma | NCT06424626 | Melanoma Mucosal Melanom... Metastatic Mela... | AK104+Axitinib AK112+Axitinib | 18 Years - 70 Years | Peking University Cancer Hospital & Institute | |
| Molecular Characterization of Primary Mucosal Melanoma | NCT03319693 | Mucosal Melanom... | Somatic Genetic | 18 Years - | CHU de Reims | |
| A Study to Assess YH003 in Combination With Pebolizumab and Albumin Paclitaxel Injection in Subjects With Unresectable/Metastatic Mucosal Melanoma | NCT05420324 | Mucosal Melanom... | YH003 Pembrolizumab albumin paclita... | 18 Years - | Eucure (Beijing) Biopharma Co., Ltd | |
| Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | NCT03241186 | Mucosal Melanom... | Ipilimumab Nivolumab Nivolumab | 18 Years - | Hoosier Cancer Research Network | |
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma | NCT06319196 | Cutaneous Melan... Melanoma Stage ... Mucosal Melanom... | Opdualag Nivolumab | 18 Years - | University Health Network, Toronto | |
| A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | NCT02978443 | Acral Lentigino... Mucosal Melanom... | Nivolumab Ipilimumab | 18 Years - | Georgetown University | |
| Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma | NCT04622566 | Mucosal Melanom... Neoadjuvant Tre... | Lenvatinib, Pem... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | NCT05111574 | Anal Melanoma Bladder Melanom... Cervical Melano... Esophageal Mela... Gallbladder Mel... Mucosal Melanom... Mucosal Melanom... Mucosal Melanom... Nasopharyngeal ... Oral Cavity Muc... Penile Mucosal ... Rectal Melanoma Recurrent Mucos... Sinonasal Mucos... Stage II Vulvar... Stage III Vulva... Stage IV Vulvar... Urethral Melano... Vaginal Melanom... Vulvar Melanoma | Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Magnetic Resona... Nivolumab Placebo Adminis... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma | NCT01092728 | Melanoma | Dasatinib Surgical Resect... | 18 Years - | M.D. Anderson Cancer Center | |
| Atypical MOLes and Melanoma Early Detection Study (MoleMed) | NCT04353050 | Melanoma Melanoma (Skin) Moles Nevus Nevus, Blue Nevus, Pigmente... Nevus, Spitz Nevi, Spindle C... Nevi, Dysplasti... Dysplastic Nevu... Mucosal Melanom... Mucosal Melanos... | Non-invasive ad... | 18 Years - | Russian Academy of Medical Sciences | |
| Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | NCT03220009 | Cervical Carcin... Esophageal Carc... Mucosal Melanom... Mucosal Melanom... Oral Cavity Muc... Recurrent Melan... Stage II Vulvar... Stage III Vulva... Stage IIIA Vulv... Stage IIIB Vulv... Stage IIIC Vulv... Stage IV Oral C... Stage IV Vulvar... Stage IVA Oral ... Stage IVB Oral ... Stage IVC Oral ... Vaginal Carcino... | Conventional Su... Ipilimumab Laboratory Biom... Nivolumab Patient Observa... Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma | NCT03241186 | Mucosal Melanom... | Ipilimumab Nivolumab Nivolumab | 18 Years - | Hoosier Cancer Research Network | |
| Neoadjuvant and Adjuvant Checkpoint Blockade | NCT02519322 | Cutaneous Melan... Mucosal Melanom... Ocular Melanoma Stage III Acral... Stage IIIB Cuta... Stage IIIB Uvea... Stage IIIC Cuta... Stage IIIC Uvea... Stage IV Acral ... Stage IV Cutane... Stage IV Uveal ... | Ipilimumab Laboratory Biom... Nivolumab Relatlimab Therapeutic Con... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma | NCT01864538 | Metastatic Mela... | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma | NCT01092728 | Melanoma | Dasatinib Surgical Resect... | 18 Years - | M.D. Anderson Cancer Center | |
| Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | NCT05628883 | Metastatic Mela... Unresectable Me... Acral Melanoma Mucosal Melanom... Cutaneous Melan... Ocular Melanoma Uveal Melanoma Iris Melanoma Conjunctival Me... Non-Cutaneous M... | TBio-4101 Cyclophosphamid... Fludarabine Interleukin-2 | 18 Years - 75 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | NCT05398640 | Unresectable Me... Metastatic Mela... | Lifileucel | 18 Years - | Iovance Biotherapeutics, Inc. | |
| A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma | NCT03698019 | Acral Lentigino... Clinical Stage ... Clinical Stage ... Mucosal Melanom... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Pembrolizumab Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
